<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04592666</url>
  </required_header>
  <id_info>
    <org_study_id>ALMO-PEME-CAR-01</org_study_id>
    <nct_id>NCT04592666</nct_id>
  </id_info>
  <brief_title>Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer</brief_title>
  <acronym>APPEAL</acronym>
  <official_title>Almonertinib Plus Pemetrexed and Carboplatin Versus Almonertinib Alone in Advanced NSCLC With EGFR T790M After First- or Second-generation TKIs Therapy: a Randomized, Controlled, Open-label, Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Almonertinib Plus Pemetrexed and Carboplatin Versus Almonertinib Alone in Advanced NSCLC With&#xD;
      EGFR T790M After First- or Second-generation TKIs Therapy: a Randomized, Controlled,&#xD;
      Open-label, Phase 2 Study&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 9, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>from the first cycle of treatment (day one) to two month after the last cycle (each cycle is 21 days)</time_frame>
    <description>progression free survival</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Lung Cancer, Non-small Cell</condition>
  <condition>EGFR T790M</condition>
  <condition>EGFR Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Combinational therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single TKI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Almonertinib</intervention_name>
    <description>the standard therapy of single agent almonertinib</description>
    <arm_group_label>Combinational therapy</arm_group_label>
    <arm_group_label>Single TKI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>standard dose</description>
    <arm_group_label>Combinational therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC=5</description>
    <arm_group_label>Combinational therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between 18 and 75 years old (including 18 and 75 years old);&#xD;
&#xD;
          2. Histologically or cytologically confirmed locally advanced or metastatic (STAGE&#xD;
             IIIB-IV) NSCLC does not accept simple sputum smear-based diagnosis;&#xD;
&#xD;
          3. Previous genetic tests confirmed egFR-sensitive mutations, and received one or two&#xD;
             generations of EGFR TKI treatment. After drug resistance, it was confirmed to be&#xD;
             positive for EGFR T790M mutation by biopsy or free DNA test.&#xD;
&#xD;
          4. The patient has at least one tumor lesion that has not received local treatment such&#xD;
             as radiation or biopsy in the screening stage, and can be accurately measured at&#xD;
             baseline, with the longest diameter ≥ 10mm at baseline (short diameter ≥ 15mm if lymph&#xD;
             nodes are involved).The measurement method chosen is suitable for accurate repeated&#xD;
             measurements and can be computed tomography (CT) or magnetic resonance imaging&#xD;
             (MRI).If there is only one measurable lesion and no previous local treatment such as&#xD;
             irradiation, it can be accepted as the target lesion for baseline evaluation of tumor&#xD;
             lesions after at least 14 days of diagnostic biopsy.&#xD;
&#xD;
          5. Life expectancy is at least 3 months;&#xD;
&#xD;
          6. ECOG score: 0-1, with no significant clinical deterioration in the past 2 weeks;&#xD;
&#xD;
          7. The main organs function normally, that is, they meet the following standards:&#xD;
&#xD;
        blood routine examination standards must be in accordance with no blood transfusion and&#xD;
        adjuvant therapies (14 days) : A. Hemoglobin (HB) ≥90 g/L; B. Absolute value of neutrophils&#xD;
        (ANC) ≥1.5×109/L; C. Platelet (PLT) ≥100×109/L; D. Total bilirubin (TBIL) &lt;1.5 times the&#xD;
        upper limit of normal value (ULN); E. Alanine aminotransferase (ALT) and aspartate&#xD;
        aminotransferase (AST) &lt;2.5×ULN, if accompanied by liver metastasis, ALT and AST&lt; 5×ULN; F.&#xD;
        Serum Cr&lt;1.25×ULN or endogenous creatinine clearance rate (CCr) &gt; 45 ml/min&#xD;
        (Cockcroft-Gault formula);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have received three generations of EGFR-TKI treatment;&#xD;
&#xD;
          2. Patients with mixed small cell lung cancer components;&#xD;
&#xD;
          3. Patients with advanced or metastatic disease who have received palliative&#xD;
             chemotherapy, or patients with tumor recurrence and metastasis within 6 months after&#xD;
             radical surgery with adjuvant chemotherapy;&#xD;
&#xD;
          4. Patients with symptomatic brain metastasis, meningeal metastasis or spinal cord&#xD;
             compression;&#xD;
&#xD;
          5. Patients with previous diagnosis of interstitial pneumonia;&#xD;
&#xD;
          6. Uncontrolled hypertension (systolic blood pressure ≥140 mmHg or diastolic blood&#xD;
             pressure ≥90 mmHg, despite the best medication);&#xD;
&#xD;
          7. with severe cardiovascular disease: Ⅱ magnitude of myocardial ischemia and myocardial&#xD;
             infarction, poor control of cardiac arrhythmias (including QTc interphase male 450,&#xD;
             female 470 ms or ms or higher);According to NYHA standard, Ⅲ ~ Ⅳ cardiac&#xD;
             insufficiency, or heart colour to exceed revealed left ventricular ejection fraction&#xD;
             (LVEF) &lt; 50%;&#xD;
&#xD;
          8. abnormal coagulation function (INR &gt;1.5 or prothrombin time (PT) &gt; ULN+4 seconds or&#xD;
             APTT &gt; 1.5uln), bleeding tendency or receiving thrombolytic or anticoagulant therapy;&#xD;
             Note: Under the condition that the international standard ratio of prothrombin time&#xD;
             (INR) ≤1.5, low-dose heparin (daily dosage for adults ranges from 66,000 to 12,000 U)&#xD;
             or low-dose aspirin (daily dosage ≤100 mg) is allowed for preventive purposes.&#xD;
&#xD;
          9. Peripheral neuropathy ≥CTCAE 2 is present, except for trauma;&#xD;
&#xD;
         10. Respiratory syndrome (≥CTCAE level 2 dyspnea), uncontrolled serous cavity effusion&#xD;
             (including pleural effusion, ascites and pericardial effusion);&#xD;
&#xD;
         11. A wound or fracture that has not been healed for a long time;&#xD;
&#xD;
         12. Severe infections requiring systemic antibiotics;&#xD;
&#xD;
         13. Decompensated diabetes mellitus or other contraindications of high-dose glucocorticoid&#xD;
             therapy;&#xD;
&#xD;
         14. Active hepatitis C and/or hepatitis B infection (hepatitis B: HBsAg positive with HBV&#xD;
             DNA≥500IU/mL;Hepatitis C: HCV RNA positive);&#xD;
&#xD;
         15. Factors that significantly affect oral drug absorption, such as inability to swallow,&#xD;
             chronic diarrhea, and intestinal obstruction;&#xD;
&#xD;
         16. Had major surgery or severe traumatic injury, fracture or ulcer within the first 4&#xD;
             weeks;&#xD;
&#xD;
         17. Any contraindications for platinum (carboplatin) and cytotoxic drug (Pemetrexed)&#xD;
             treatment;&#xD;
&#xD;
         18. Other conditions deemed inappropriate by the researcher for inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Jialei Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>EGFR</keyword>
  <keyword>Combination therapy</keyword>
  <keyword>Almonertinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>based on preliminary results</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

